World

Omicron reported in 57 countries, hospitalisations set to rise, WHO says

2 minute read
1/5

A street vendor wears a mask as he sells goods during the coronavirus disease (COVID-19) outbreak in Harare, Zimbabwe, July 8, 2021. REUTERS/Philimon Bulawayo

Register now for FREE unlimited access to Reuters.com

GENEVA, Dec 8 (Reuters) - The Omicron variant has been reported in 57 nations and the number of patients needing hospitalisation is likely to rise as it spreads, the World Health Organization said on Wednesday.

The WHO, in its weekly epidemiological report, said more data was needed to assess the severity of disease caused by the Omicron variant and whether its mutations might reduce protection from vaccine-derived immunity.

"Even if the severity is equal or potentially even lower than for Delta variant, it is expected that hospitalisations will increase if more people become infected and that there will be a time lag between an increase in the incidence of cases and an increase in the incidence of deaths," it said.

Register now for FREE unlimited access to Reuters.com

On Nov. 26, the WHO declared the Omicron variant, which was first detected in southern Africa, a variant of concern. It is the fifth SARS-CoV-2 strain to carry such a designation.

The number of reported COVID-19 cases in South Africa doubled in the week to Dec. 5 to more than 62,000 and "very large" increases in incidence have been seen in Eswatini, Zimbabwe, Mozambique, Namibia and Lesotho, it said.

The spread of Omicron, coupled with enhanced testing and low vaccination rates may have played a role, it added.

Referring to the risk of reinfection, the WHO said: "Preliminary analysis suggests that the mutations present in the Omicron variant may reduce neutralising activity of antibodies resulting in reduced protection from natural immunity."

"There is a need for more data to assess whether the mutations present on the Omicron variant may result in reduced protection from vaccine-derived immunity and data on vaccine effectiveness, including the use of additional vaccination doses," it said.

The Omicron variant can partially evade the protection from two doses of the COVID-19 vaccine produced by Pfizer Inc (PFE.N) and BioNTech (22UAy.DE), the research head of a laboratory at the Africa Health Research Institute in South Africa said on Tuesday, reporting the results of a small study. read more

Register now for FREE unlimited access to Reuters.com
Reporting by Stephanie Nebehay; Editing by Andrew Heavens and Edmund Blair

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters